WO2008019782A2 - Dispersionen von nanoharnstoffen. enthaltend wirkstoffe - Google Patents
Dispersionen von nanoharnstoffen. enthaltend wirkstoffe Download PDFInfo
- Publication number
- WO2008019782A2 WO2008019782A2 PCT/EP2007/006989 EP2007006989W WO2008019782A2 WO 2008019782 A2 WO2008019782 A2 WO 2008019782A2 EP 2007006989 W EP2007006989 W EP 2007006989W WO 2008019782 A2 WO2008019782 A2 WO 2008019782A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- dispersions
- dispersion
- polyisocyanates
- hydrophilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/0804—Manufacture of polymers containing ionic or ionogenic groups
- C08G18/0819—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups
- C08G18/0823—Manufacture of polymers containing ionic or ionogenic groups containing anionic or anionogenic groups containing carboxylate salt groups or groups forming them
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Definitions
- the present invention relates to dispersions of nanoureas containing active ingredients, a process for their preparation, and their use.
- the equipment of a plastic with an active ingredient often fails because the active ingredient is incompatible with the plastic and therefore a homogeneous incorporation does not succeed.
- the locally different concentration of active ingredient is a great disadvantage, as this creates areas that are free of active ingredient and thus ineffective.
- the mechanical properties of the plastic can be very adversely affected inhomogeneous incorporation.
- plastic is to be modified by dissolving the active ingredient and mixing it with the (optionally also dissolved) plastic
- this method has the following disadvantages: on the one hand, solvents which are equally suitable for all active substances and plastics can not be found; On the other hand, the use of organic solvents is fundamentally disadvantageous, i.a. because residues of it can remain in the product, which would not be acceptable for medical devices, for example.
- the equipment of plastics with active ingredients is particularly important in the field of medical technology.
- the bacterial colonization of medical devices is a major problem because this is often the initial step for a subsequent serious infection of the patient being treated.
- Numerous methods for antimicrobial finishing of catheters have therefore been proposed, whereby it is possible to equip the catheter material itself (eg, silicone, polyurethane, latex or PVC) as well as a coating with an antimicrobial material.
- antimicrobial coatings it has been proposed, for example, to deposit a pure metal layer of doped silver (US 5,320,908, US 5,395,651 & US 5,965,204); however, the adhesion of these (brittle) coatings to the catheter material is poor.
- DE-A 10 2004 030504 describes the use of pH-sensitive polymers for the coating of macroscopic oral dosage forms for selective release of active ingredient.
- the applicability is limited to areas where a targeted change of the pH in the environment should cause a release of the active ingredients.
- biodegradable polymers are used to coat active ingredients. Problem is the lack of stability of such compounds in aqueous systems due to their susceptibility to hydrolysis or microbial degradation.
- EP 0429187 retard formulations of cross-linked polyvinylpyrrolidinones which include a certain type of steroids and can release delayed. The procedure described is limited to the use of a certain class of steroids.
- the object of the present invention was therefore to provide a drug-compatible plastic matrix, from which both coatings and materials and moldings can be produced and which exhibits a so-called controlled release behavior, ie a controlled release characteristic which may be delayed over a period of time.
- the present invention therefore provides a process for the preparation of active substance-containing, aqueous nanoheamate dispersions in which
- active substances are defined as elements or chemical compounds which have an effect on living systems, in particular prions, viruses, bacteria, cells, fungi and organisms.
- biocidal agents e.g. pesticidal, fungicidal, algicidal, insecticidal, herbicidal, spermicidal, parasiticidal, antibacterial (bactericidal), bacteriostatic, antibiotic, antifungal (fungi destroying); antiviral (virus destroying), virostatic and / or antimicrobial (microbe destroying) act.
- active ingredients and the combination of, for example, with auxiliaries, binders, neutralizing agents or additives are possible.
- Other active ingredients and combinations for example active substances from the field of human medicine or veterinary medicine can be used.
- hydrophilicized polyisocyanates it is possible to use all NCO-group-containing compounds which are known to the person skilled in the art and which are nonionic, (potentially) anionic or (potentially) cationically hydrophilized.
- the hydrophilized polyisocyanates preferably have at least one nonionically hydrophilizing structural unit.
- the hydrophilization of the polyisocyanates is particularly preferably carried out exclusively by nonionically hydrophilicizing groups.
- Such nonionic hydrophilicizing groups are preferably introduced into polyisocyanates by reaction with polyethers, these polyethers preferably being monofunctional with respect to NCO group-reactive groups contained therein.
- NCO-reactive groups are hydroxy, thiol or amino functions. In principle, however, these can also have more than one NCO-reactive group.
- polyethers of the abovementioned type used for the hydrophilicization are typically polyoxyalkylene ethers in which preferably from 30% by weight to 100% by weight of the oxyalkylene units are oxyethylene groups and up to 70% by weight oxypropylene units.
- Such polyethers are accessible in a manner known per se by alkoxylation of suitable starter molecules (for example in Ullmanns Encyclopadie der ischen Chemie, 4th Edition, Volume 19, Verlag Chemie, Weinheim, pages 31-38).
- Suitable starter molecules are, for example, saturated monoalcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol, the isomers pentanols, hexanols, octanols and nonanols, n-decanol, n-dodecanol, n-tetradecanol, n Hexadecanol, n-octadecanol, cyclohexanol, the isomeric methylcyclohexanols or hydroxymethylcyclohexane, 3-ethyl-3-hydroxymethyloxetane or tetrahydrofurfuryl alcohol, diethylene glycol monoalkyl ethers such as diethylene glycol monobutyl ether, unsaturated alcohols such as allyl alcohol, 1,1-dimethylallyl alcohol or
- Alkylene oxides which are suitable for the alkoxylation reaction are, in particular, ethylene oxide and propylene oxide, which can be used in any desired order or else as a mixture in the alkoxylation reaction.
- the hydrophilized polyisocyanates are based on those skilled in the art known aliphatic, cycloaliphatic, araliphatic and aromatic polyisocyanates having more than one NCO group per molecule and an isocyanate content of 0.5 to 50, preferably 3 to 30, particularly preferably 5 to 25 wt. % or mixtures thereof.
- polyisocyanates examples include butylene diisocyanate, tetramethylene diisocyanate, cyclohexane-1, 3- and 1,4-diisocyanate, hexamethylene diisocyanate (HDI), 1-isocanato-3,3,5-trimethyl-5-isocyanato-methylcyclohexane (isophorone diisocyanate, IPDI), 2,4,4
- Trimethylhexamethylene diisocyanate isocyanatomethyl-1, 8-octane diisocyanate, methylene bis (4-isocyanatocyclohexane), tetramethylxylylene diisocyanate (TMXDI) or triisocyanatononane (TIN, 4-isocyanatomethyl-1 ⁇ -octane diisocyanate) and optionally also mixtures with other di- or polyisocyanates
- aromatic polyisocyanates such as 1, 4-phenylene diisocyanate, 2,4- and / or 2,6-toluene diisocyanate (TDI), diphenylmethane-2,4 'and / or 4,4'-diisocyanate (MDI), triphenylmethane 4,4'-diisocyanate, naphthylene-1, 5-diisocyanate.
- hydrophilized polyisocyanates of component A) are preferably based on polyisocyanates or polyisocyanate mixtures of the abovementioned type having exclusively aliphatically or cycloaliphatically bonded isocyanate groups or any desired mixtures thereof.
- hydrophilized polyisocyanates are particularly preferably based on hexamethylene diisocyanate, isophorone diisocyanate or the isomeric bis (4,4'-isocyanatocyclohexyl) methanes, and also mixtures of the abovementioned diisocyanates.
- Catalysts can be used to prepare the nanourea dispersions. Suitable examples are tertiary amines, tin, zinc or bismuth compounds or basic salts.
- Suitable tertiary amines are triethylamine, tributylamine, dimethylbenzylamine, dicyclohexylmethylamine, dimethylcyclohexylamine, N, N, N ', N'-tetramethyl-diamino-diethyl ether, bis (dimethylaminopropyl) urea, N-methyl- and N-ethylmorpholine, N, respectively 1 N '
- DMDEE Dimorpholinodiethyl ether
- N-cyclohexylmorpholine N, N, N ', N'-
- Tetramethylethylenediamine N, N, N ', N'-tetramethylbutanediamine, N, N, N', N'- Tetramethylhexanediamine-1,6-pentamethyldiethylenetriamine, dimethylpiperazine, N-dimethylaminoethylpiperidine, 1,2-dimethylimidazole, N-hydroxypropylimidazole, 1-azabicyclo- (2,2,0) -octane, 1,4-diazabicyclo- (2,2,2 ) octane (Dabco) and alkanolamine compounds such as triethanolamine, triisopropanolamine, N-methyl- and N-ethyl-diethanolamine, dimethyl-aminoethanol, 2- (N, N-dimethylaminoethoxy) ethanol, N 1 N ', N-Tris - (dialkylaminoalkyl) hexahydrotriazines, for example N, N,
- tin salts such as tin dioctoate, tin diethylhexoate, dibutyltin dilaurate and / or dibutyldilauryltin mercaptide, 2,3-dimethyl-3,4,5,6-tetrahydropyrimidine, tetraalkylammonium hydroxides, such as tetramethylammonium hydroxide, alkali metal hydroxides, such as sodium hydroxide, Alkali alcoholates, such as sodium and potassium isopropoxide and / or alkali metal salts of long-chain fatty acids having 10 to 20 carbon atoms and optionally pendant OH groups.
- tin salts such as tin dioctoate, tin diethylhexoate, dibutyltin dilaurate and / or dibutyldilauryltin mercaptide, 2,3-dimethyl-3,4,5,6-tetrahydropyrimidine,
- catalysts are tertiary amines, very particular preference is given to triethylamine, ethyldiisopropylamine and 1,4-diazabicyclo [2,2,2] octane.
- These catalysts are typically used in amounts of 0.01 to 8 wt .-%, preferably from 0.05 to 5 wt .-%, particularly preferably from 0.1 to 3 wt .-%, based on the total solids content of the resulting dispersion used. It is also possible to add mixtures of the catalysts.
- solvents such as N-methylpyrrolidone, N-ethylpyrrolidone, methoxypropyl acetate, dimethyl sulfoxide, methoxypropyl acetate, acetone and / or methyl ethyl ketone to the mixture.
- volatile solvents such as acetone and / or methyl ethyl ketone can be removed by distillation. Preference is given to the preparation without solvent and the use of acetone or methyl ethyl ketone, the preparation without solvent being particularly preferred.
- the above-described hydrophilicized polyisocyanates are dispersed in an aqueous medium, if appropriate in the presence of catalysts.
- the dispersion and reaction are preferably carried out by mixing through an agitator or other types of mixing such as pumping, static mixer, spiked mixer, nozzle jet disperser, rotor and stator or under the influence of ultrasound.
- an agitator or other types of mixing such as pumping, static mixer, spiked mixer, nozzle jet disperser, rotor and stator or under the influence of ultrasound.
- the molecular ratio of NCO groups of the hydrophilized polyisocyanate to water is preferably 1: 100 to 1: 5, more preferably 1: 30 to 1: 10.
- hydrophilized polyisocyanate in one portion into the water.
- a continuous addition of the hydrophilized polyisocyanate for example over a period of 30 minutes to 20 hours is possible.
- preference is given to a portionwise addition wherein the number of portions 2 to 50, preferably 3 to 20, particularly preferably 4 to 10, wherein the portions may be the same or different sizes.
- the waiting time between the individual portions is typically 5 minutes to 12 hours, preferably 10 minutes to 8 hours, more preferably 30 minutes to 5 hours.
- hydrophilized polyisocyanate distributed over a period of 1 hour to 24 hours, preferably 2 hours to 15 hours.
- the boiler temperature is typically 10 to 80 0 C, preferably 20 to 70 0 C and particularly preferably 25 to 5O 0 C.
- the evacuation takes place up to an internal pressure of 1 to 900 mbar, preferably 10 to 800 mbar, particularly preferably 100 to 400 mbar.
- the duration of this subsequent to the actual reaction degassing is typically 1 minute to 24 hours, preferably 10 minutes to 8 hours. Degassing is also possible by increasing the temperature without evacuation.
- the nanourea dispersion is mixed, e.g. by stirring.
- the solids content of the present urea particles in the dispersion obtained according to A) is typically from 10 to 60% by weight, preferably from 20 to 50% by weight, particularly preferably from 30 to 45%.
- the incorporation of the active ingredients can take place during or after particle production.
- the active ingredients can already be present during the dispersion of the hydrophilized polyisocyanate or can be metered in parallel with them or added after the preparation of the particles. the. This results in at least partial absorption of the active ingredient into the particles. This uptake in the interior and / or on the surface of the particles leads to a time-distributed release characteristic of the active substance.
- residual active ingredient may be separated by filtration, for example.
- the dispersion can be freed, for example, by dialysis or ultrafiltration according to known methods of low molecular weight components.
- the amount of active ingredient based on the solids content of the present urea particles 0.0001 to 50 wt .-%, preferably 1 to 20 wt .-%, particularly preferably 5 to 15 wt .-%.
- the amount of active ingredients generally depends on the amount of the respective active ingredient required for the respective indication.
- Active ingredients which are poorly soluble or not at all soluble in water are preferably mixed with the hydrophilized polyisocyanate, if appropriate with the aid of cosolvents, and then dispersed into the aqueous medium.
- these active compounds preferably have no NCO-reactive groups or if they nevertheless have such groups, the conversion to urea must be designed in such a way that there is no appreciable reaction of the NCO groups with the active ingredient. If solvents are used for incorporation of active ingredients, they are preferably removed again by distillation after the incorporation.
- temperatures of 25 to 100 0 C are usually chosen.
- auxiliaries and additives such as, for example, stabilizers, surfactants, solubilizers, neutralizing agents, scavengers for reactive groups, leveling agents and / or radical scavengers.
- Another object of the invention are the dispersions obtainable by the process according to the invention and the active ingredient-containing nanoscale urea particles contained therein.
- nanourea particles have an average particle size of 10 to 300 nm, preferably 20 to 150 nm, determined by means of laser correlation spectroscopy.
- active substance-containing nanoheamate dispersions can also be dried by methods which are conventional in the art, such as distillation, freeze-drying or spray-drying.
- Both the dispersions obtained in accordance with the invention and the particles contained therein are valuable starting materials for the preparation of coatings containing active substances, materials and moldings which are preferably based on polyurethanes.
- the drug-containing nanorubber dispersions can be used as such, especially if the coating formulation itself contains components dispersed in water such as e.g. contains the binder.
- Preferred binders in such coating formulations are polyurethanes, poly (meth) acrylates, polyesters and silicones of all types. Particularly preferred are polyurethanes which can be used in the form of aqueous dispersions, solutions in organic solvents or also free from solvents. One- and two-component polyurethanes can be used in the same way.
- This coating formulation can then be applied to an article in any manner, for example by spraying, spraying, brushing, dipping, flooding or by means of rollers and doctor blades.
- Suitable substrates are, for example, metals, plastics, in particular polyethylene, polypropylene, polytetrafluoroethylene, polyurethanes, silicones, polyvinyl chloride, poly (meth) acrylates, polycarbonates, polyesters, wood, cloth, fabric or glass.
- the application of the coating formulation and the drying and / or curing can be carried out before, during or after shaping of the article. The drying and / or curing takes place at room temperature or elevated temperatures, optionally under reduced pressure.
- Materials and moldings which can be prepared with the aid of the particles and dispersions according to the invention or coated with coatings containing the particles according to the invention are all known utensils in which, for example by frequent contact a microbial load occurs (eg handles of any kind), but also Articles for storage, transport (eg pipes) or processing of liquid media can be understood hereunder.
- articles from the field of medical technology such as, for example, catheters, tubes, vessels, accesses, implants, artificial organs (except semi and within the body), prostheses, vascular grafts (stents), optical aids (eg contact lenses), endoscopes and wound dressings.
- the indicated viscosities were determined by means of rotational viscometry according to DIN 53019 at 23 ° C. with a rotational viscometer from Anton Paar Germany GmbH, Ostfildern, DE.
- NCO contents were determined volumetrically in accordance with DIN-EN ISO 1 1909, unless expressly stated otherwise.
- the indicated particle sizes were determined by means of laser correlation spectroscopy (device: Malvern Zetasizer 1000, Malver Inst. Limited).
- the solids contents were determined according to DIN-EN ISO 3251.
- Control for free NCO groups was performed by IR spectroscopy (band at 2260 cm -1 ).
- the concentrations of the silver ions were determined spectroscopically in accordance with DIN ISO 17025.
- Dialysis was carried out with Float-A-Lyzer® floating dialysis tubing from Spectra / Por®.
- the tubing was cellulose ester membranes with a nominal cut-off of 25,000 g / mol.
- the membranes were rinsed with deionized water before use and conditioned in a water bath.
- Bayhydur ® VP LS 2336 hydrophilicized polyisocyanate based on hexamethylene carbonate, solvent-free, viscosity about 6800 mPa s, the isocyanate content of about 16.2%, Bayer Materials- cienceAG, Leverkusen, DE.
- Impranil® DLN Anionically hydrophilicized, non-branched, aliphatic polyester-polyurethane dispersion in water with a solids content of approx. 40%) Bayer MaterialScience
- Isofoam ® 16 defoamers, Petrofer chemistry, Hildesheim, DE.
- the other chemicals were purchased in the fine chemicals trade at Sigma-Ald ⁇ ch GmbH, Taufkirchen, DE
- the resulting white dispersion had the following properties:
- Viscosity (viscometer, 23 ° C): ⁇ 50 mPas
- the resulting white dispersion had the following properties:
- Viscosity (viscometer, 23 ° C): ⁇ 50 mPas
- the resulting white dispersion had the following properties:
- Viscosity (viscometer, 23 ° C): ⁇ 50 mPas
- Staphylococcus epidermidis 498 cells and Bacillus subtilis 168 cells were plated on agar plates to form a visible cell lawn on the agar after overnight incubation at 37 ° C.
- OD 600 O 1 I adjusted, 200 ⁇ l plated per plate, dried at room temperature for one hour.
- One hole was punched out of each of the middle plates.
- drug-containing nanourea dispersions 100 ul), which were prepared analogously to Example 2 and in which the active ingredient was contained exclusively in bound form, filled.
- the active ingredient-loaded nanourea dispersions according to the invention have a controlled release profile based on the active substance contained therein in bound form. This can be seen from the proven antibacterial effect, since the dispersants used As a result of the previous dialysis, ions themselves no longer contained any free unbound active ingredient and the antibacterial effect can only occur if bound active ingredient has been released again.
- Example 5 In an overnight culture of Staphylococcus epidermidis (ATC 14990) a test according to Example 5 was performed. The underlying active ingredient-loaded dispersions F to K were again prepared analogously to Example 2. As comparisons L to O, aqueous solutions containing various concentrations of ciprofloxacin (Cipro) were tested.
- Example 1 900 g of the nanoheamate dispersion from Example 1 were mixed with 36 g of silver nitrate while stirring in a beaker. The dispersion was stirred for 24 hours at room temperature and then stored for 5 months in a sealed bottle.
- the water was then exchanged for new deionized water after 3, 7 and 51 days (counted from the first water change) and the concentration of silver ions was analyzed in each case.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Surgery (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polyurethanes Or Polyureas (AREA)
- Medicinal Preparation (AREA)
- Paints Or Removers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07801542A EP2054098A2 (de) | 2006-08-18 | 2007-08-08 | Dispersionen von nanoharnstoffen. enthaltend wirkstoffe |
BRPI0716049-6A2A BRPI0716049A2 (pt) | 2006-08-18 | 2007-08-08 | dispersÕes de nanourÉias, contendo substÂncias ativas |
JP2009524930A JP2010501016A (ja) | 2006-08-18 | 2007-08-08 | 活性成分を含有するナノ尿素の分散液 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006038940A DE102006038940A1 (de) | 2006-08-18 | 2006-08-18 | Dispersionen von Nanoharnstoffen, enthaltend Wirkstoffe |
DE102006038940.9 | 2006-08-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008019782A2 true WO2008019782A2 (de) | 2008-02-21 |
WO2008019782A3 WO2008019782A3 (de) | 2009-02-12 |
Family
ID=38738912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/006989 WO2008019782A2 (de) | 2006-08-18 | 2007-08-08 | Dispersionen von nanoharnstoffen. enthaltend wirkstoffe |
Country Status (8)
Country | Link |
---|---|
US (2) | US20080044474A1 (de) |
EP (1) | EP2054098A2 (de) |
JP (1) | JP2010501016A (de) |
CN (1) | CN101505808A (de) |
BR (1) | BRPI0716049A2 (de) |
DE (1) | DE102006038940A1 (de) |
RU (1) | RU2009109578A (de) |
WO (1) | WO2008019782A2 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006038940A1 (de) * | 2006-08-18 | 2008-02-21 | Bayer Materialscience Ag | Dispersionen von Nanoharnstoffen, enthaltend Wirkstoffe |
EP2103316A1 (de) * | 2008-03-20 | 2009-09-23 | Bayer MaterialScience AG | Hydrophile Polyurethandispersionen |
EP2108383A1 (de) * | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medizinische Geräte mit einer antibakteriellen Polyurethanharnstoffbeschichtung |
EP2108382A1 (de) * | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Silberhaltige Polyurethanharnstofflösung |
DE102008025613A1 (de) * | 2008-05-28 | 2009-12-03 | Bayer Materialscience Ag | Hydrophile Polyurethanbeschichtungen |
TWI392697B (zh) * | 2008-05-30 | 2013-04-11 | Univ Nat Chunghsing | The silver particle-containing aqueous polyurethane pot synthesis of |
EP2331156B1 (de) | 2008-09-04 | 2012-02-29 | Bayer MaterialScience AG | Tcd-basierte hydrophile polyurethanlösungen |
EP2687552A1 (de) * | 2012-07-17 | 2014-01-22 | Huntsman International Llc | Verwendung von Polyharnstoff-Nanopartikeln als Leistungsmodifikatoren in Polyurethanmaterialien |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1264812A2 (de) * | 2001-06-05 | 2002-12-11 | COMPO GmbH & Co.KG | Düngemittel mit verzögerter Freisetzung und Verfahren zu dessen Herstellung. |
WO2003082459A1 (fr) * | 2002-03-28 | 2003-10-09 | Centre National De La Recherche Scientifique (Cnrs) | Capsules composites biocompatibles |
US6875448B1 (en) * | 1999-09-03 | 2005-04-05 | Chugai Seiyaku Kabushiki Kaisha | Method of intracellular sustained-release of drug and preparations |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2627073C2 (de) * | 1976-06-16 | 1983-12-29 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von stabilen Dispersionen |
GB1598451A (en) * | 1977-01-17 | 1981-09-23 | Netherlands Central Org Scient | Antifungal and/or antibacterial organotin compounds there preparation and uses |
US4581028A (en) * | 1984-04-30 | 1986-04-08 | The Trustees Of Columbia University In The City Of New York | Infection-resistant materials and method of making same through use of sulfonamides |
US5320908A (en) * | 1989-05-04 | 1994-06-14 | Ad Tech Holdings Limited | Deposition of an extremely thin silver layer on a nonconducting substrate |
FI95816C (fi) * | 1989-05-04 | 1996-03-25 | Ad Tech Holdings Ltd | Antimikrobinen esine ja menetelmä sen valmistamiseksi |
JPH0859770A (ja) * | 1994-08-15 | 1996-03-05 | Dainippon Ink & Chem Inc | ポリウレタンポリ尿素架橋微粒子分散体及びその製造方法 |
GB9502253D0 (en) * | 1995-02-06 | 1995-03-29 | Giltech Ltd | The effects of antibacterial agents on the behaviour of mouse fibroblasts in vitro |
US6132420A (en) * | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
JP4176832B2 (ja) * | 1996-02-02 | 2008-11-05 | インターシア セラピューティクス, インコーポレイティド | 移植可能な系を用いる活性剤の持続投与 |
US6395292B2 (en) * | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6020004A (en) * | 1997-04-17 | 2000-02-01 | Amgen Inc. | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
US6224579B1 (en) * | 1999-03-31 | 2001-05-01 | The Trustees Of Columbia University In The City Of New York | Triclosan and silver compound containing medical devices |
KR20030048376A (ko) * | 2000-05-16 | 2003-06-19 | 다우 글로벌 테크놀로지스 인크. | 폴리우레탄 분산액 및 이를 사용하여 제조한 필름 |
US7357949B2 (en) * | 2001-12-21 | 2008-04-15 | Agion Technologies Inc. | Encapsulated inorganic antimicrobial additive for controlled release |
DE10226932A1 (de) * | 2002-06-17 | 2003-12-24 | Bayer Ag | Strahlenhärtende Beschichtungsmittel |
DE10360368A1 (de) * | 2003-12-22 | 2005-07-21 | Bayer Materialscience Ag | Dispersionen |
DE102006038940A1 (de) * | 2006-08-18 | 2008-02-21 | Bayer Materialscience Ag | Dispersionen von Nanoharnstoffen, enthaltend Wirkstoffe |
-
2006
- 2006-08-18 DE DE102006038940A patent/DE102006038940A1/de not_active Withdrawn
-
2007
- 2007-08-08 EP EP07801542A patent/EP2054098A2/de not_active Withdrawn
- 2007-08-08 CN CNA2007800305794A patent/CN101505808A/zh active Pending
- 2007-08-08 WO PCT/EP2007/006989 patent/WO2008019782A2/de active Application Filing
- 2007-08-08 JP JP2009524930A patent/JP2010501016A/ja active Pending
- 2007-08-08 RU RU2009109578/05A patent/RU2009109578A/ru not_active Application Discontinuation
- 2007-08-08 BR BRPI0716049-6A2A patent/BRPI0716049A2/pt not_active Application Discontinuation
- 2007-08-14 US US11/891,973 patent/US20080044474A1/en not_active Abandoned
-
2009
- 2009-10-14 US US12/579,003 patent/US20100034861A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875448B1 (en) * | 1999-09-03 | 2005-04-05 | Chugai Seiyaku Kabushiki Kaisha | Method of intracellular sustained-release of drug and preparations |
EP1264812A2 (de) * | 2001-06-05 | 2002-12-11 | COMPO GmbH & Co.KG | Düngemittel mit verzögerter Freisetzung und Verfahren zu dessen Herstellung. |
WO2003082459A1 (fr) * | 2002-03-28 | 2003-10-09 | Centre National De La Recherche Scientifique (Cnrs) | Capsules composites biocompatibles |
Also Published As
Publication number | Publication date |
---|---|
EP2054098A2 (de) | 2009-05-06 |
US20080044474A1 (en) | 2008-02-21 |
WO2008019782A3 (de) | 2009-02-12 |
US20100034861A1 (en) | 2010-02-11 |
RU2009109578A (ru) | 2010-09-27 |
CN101505808A (zh) | 2009-08-12 |
DE102006038940A1 (de) | 2008-02-21 |
JP2010501016A (ja) | 2010-01-14 |
BRPI0716049A2 (pt) | 2013-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008019782A2 (de) | Dispersionen von nanoharnstoffen. enthaltend wirkstoffe | |
EP2015786B1 (de) | Biomedizinische schaumartikel | |
DE10330971B4 (de) | Verfahren zur Herstellung von Haut- oder Wundauflagen mit verkapselten, wundheilungsfördernden und/oder hautpflegenden Substanzen | |
EP2265294B1 (de) | Medizinische geräte mit hydrophilen beschichtungen | |
EP2108383A1 (de) | Medizinische Geräte mit einer antibakteriellen Polyurethanharnstoffbeschichtung | |
EP2265295B1 (de) | Hydrophile polyurethandispersionen | |
EP2108386A1 (de) | Medizinische Geräte mit einer antimikrobiellen Polyurethanharnstoffbeschichtung | |
EP2704754B1 (de) | Hydrophiler polyurethan-schaum mit geringer volumenquellung | |
EP2478028B1 (de) | Hydrophile polyurethanharnstoffdispersionen | |
EP2265296B1 (de) | Medizinische geräte mit hydrophilen beschichtungen | |
EP2108388A1 (de) | Wässrige silberhaltige nichtionische Polyurethandispersionen | |
EP2257581B1 (de) | Hydrophile polyurethanlösungen | |
WO2009143977A1 (de) | Hydrophile polyurethanbeschichtungen | |
EP2086597A1 (de) | Neuartige hydrogele auf basis aliphatischer nco-prepolymere | |
EP2331596A1 (de) | Tcd-basierte hydrophile polyurethandispersionen | |
EP2509643B1 (de) | Polyurethan-dispersionen zur versiegelung von zitzen der milchdrüse bei milchliefernden tieren | |
EP2108385A1 (de) | Silberhaltige Polyurethanharnstofflösung | |
WO2011098444A1 (de) | Wirkstofffreisetzende wundauflage | |
DE202018004305U1 (de) | PUR-Hydrogele und deren Verwendung als Wundauflage | |
DE102022117861A1 (de) | Hydrogel zur Reduktion von Biofilmen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780030579.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07801542 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 894/DELNP/2009 Country of ref document: IN Ref document number: 2007801542 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009524930 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009109578 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0716049 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090217 |